An estimated 20 million regional anesthesia blocks are performed in the USA each year. Unfortunately, studies continue to show that injection of anesthesia above 20psi, which can result in significant consequences for patients and hospitals.
In fact, up to 1% (or 200,000) procedures result in serious nerve damage, and transient nerve damage in up to 8% (or 1.6 million) procedures.¹,² These complications are preventable and can affect both patient outcomes and result in costly lawsuits for hospitals.
SAFIRA™ from Medovate gives anesthesiologists the tools to confidently take control of regional anesthesia injection. SAFIRA™ has a built-in system to help prevent injection at pressures above 20psi, which helps reduce the risk of significant or transient nerve damage.
In addition, SAFIRA™ makes regional anesthesia a one operator procedure, giving anesthesiologists control of the whole procedure.
SAFIRA™ promotes better outcomes for patients, saves time and resources, and can help reduce costs of reintervention or lawsuits.
MED Alliance Group is an ISO 13485 certified medical device distributor and has been dedicated to meeting the needs of our clinical customers and manufacturing partners since 1998. We specialize in the sales, marketing, importation, logistics and distribution of innovative, high-quality and cost-effective products found in anesthesia and respiratory, blood and transfusion therapy, EMS and emergency room, interventional radiology and cath lab, iv and vascular, as well as NICU and PICU.
 Borgeat A, Blumenthal S. Nerve injury and regional anaesthesia [Internet]. Vol. 17, Current Opinion in Anaesthesiology. 2004 [cited 2020 Mar 31]. p. 417–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17023899
 Jeng CL, Torrillo TM, Rosenblatt MA. Complications of peripheral nerve blocks. Br J Anaesth [Internet]. 2010 [cited 2020 Mar 31];105(S1):97–107. Available from: https://academic.oup.com/bja/article-abstract/105/suppl_1/i97/235950